What is HC Wainwright’s Estimate for Genmab A/S Q2 Earnings?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Investment analysts at HC Wainwright reduced their Q2 2026 earnings estimates for shares of Genmab A/S in a note issued to investors on Monday, July 13th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.42 per share for the quarter, down from their prior forecast of $0.46. HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.08 per share. HC Wainwright also issued estimates for Genmab A/S’s Q3 2026 earnings at $0.37 EPS, Q4 2026 earnings at $0.33 EPS and FY2026 earnings at $1.21 EPS.

A number of other research analysts have also weighed in on GMAB. Wolfe Research initiated coverage on Genmab A/S in a report on Friday, March 27th. They issued an “outperform” rating and a $32.00 target price on the stock. The Goldman Sachs Group upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. Truist Financial started coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, Weiss Ratings cut shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.21.

Genmab A/S Price Performance

GMAB stock opened at $28.80 on Tuesday. The company has a market capitalization of $17.96 billion, a P/E ratio of 21.82, a price-to-earnings-growth ratio of 1.87 and a beta of 0.84. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. Genmab A/S has a 52-week low of $21.00 and a 52-week high of $35.43. The business has a 50-day simple moving average of $26.49 and a two-hundred day simple moving average of $28.51.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GMAB. Terra Nova Asset Management LLC bought a new stake in Genmab A/S during the 4th quarter valued at $1,866,000. Perpetual Ltd purchased a new position in shares of Genmab A/S in the fourth quarter valued at $25,478,000. Assetmark Inc. raised its stake in shares of Genmab A/S by 2,423.8% during the 4th quarter. Assetmark Inc. now owns 233,852 shares of the company’s stock valued at $7,203,000 after purchasing an additional 224,586 shares during the period. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in shares of Genmab A/S during the 4th quarter valued at $1,331,000. Finally, Oppenheimer Asset Management Inc. lifted its holdings in Genmab A/S by 15.5% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 364,756 shares of the company’s stock worth $11,234,000 after purchasing an additional 48,894 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.